ABSTRACT

There is an increasing prevalence of epileptic patients throughout the world and new compounds are necessary to overcome this. While the current available treatment causes abnormal body movement, loss of coordination and confusion, etc. this has led to a demand for more affordable, more effective methods for epileptic patients. Aim of this research is too focused on finding alternative medicinal remedies with significant anticonvulsant activity as well as low adverse effects. This study synthesized, characterized, and evaluated anti- convulsant properties of synthetic Hydantoin hybrid of 5, 5-Diphenylimidazolidione-2, 4- dione derivatives. Hybrid between phenytoin and 1-Oxa-4-azacyclohexane Tetrahydro-1, 4- oxazine Diethylene oximide were synthesized and tested for anticonvulsant activity. MATERIAL AND METHODS: Preliminary anticonvulsant activity was performed using subcutaneous phentylenetetrazole (scPTZ) screens in Wistar rats. Standard dose of phenytoin is 100mg/kg is used in this model and dose of PTZ is 85mg/kg is used. RESULT: Among synthesized compounds the anticonvulsant activity are shown by AA, AC, AC1, AC6 and AC7 having the highest protection (80%) in the scPTZ test at a dose of 85mg/kg whereas thecompound AC (step-III) product shows promising anticonvulsant effect in the PTZ model. CONCLUSION: Derivatives developed in this study provide new classes of anti-convulsant effect, and further optimization like bioavailability and lowering the side effect as much as possible can be performed using this information. Keywords: 5, 5-Diphenylimidazolidione-2, 4-dione, In-vivo study, scPTZ, Anti- convulsant, Morpholine
Publication date: 01/10/2023

https://ijbpas.com/pdf/2023/October/MS_IJBPAS_2023_7458.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.10.7458